Hexvix (Hexaminolevulinate)

Hexvix is indicated for the detection of non‑muscle invasive bladder cancer during cystoscopic examination, allowing clinicians to identify malignant urothelial tissue that may be difficult to see with standard white‑light imaging.

• Enhances visualization of carcinoma in situ lesions.
• Improves identification of papillary tumors.
• Assists in mapping tumor extent before resection.
• Used in conjunction with blue‑light cystoscopy (photodynamic diagnosis).
• May be employed in surveillance cystoscopies to detect recurrent disease.
• Supports decision‑making for intravesical therapy.

• Hexvix contains hexaminolevulinate, a prodrug that is preferentially taken up by malignant urothelial cells. Inside these cells, the compound is metabolized to protoporphyrin IX, a fluorescent porphyrin. When the bladder is illuminated with blue light (approximately 375–440 nm), protoporphyrin IX emits red‑orange fluorescence, delineating cancerous lesions from normal tissue. This selective accumulation and fluorescence effectively enable photodynamic diagnosis during cystoscopy, providing clinicians with a clinically useful visual contrast.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of the agent.

Common

• Mild bladder irritation or dysuria, usually resolving within 24 hours after the procedure.
• Transient hematuria that may appear during or shortly after instillation and typically clears spontaneously.
• Temporary urinary urgency or frequency, often mild and self‑limited.
• Flank or suprapubic discomfort that does not require additional medication.
• Nausea or mild headache reported by a small number of patients.

Serious

• Severe allergic reaction, including anaphylaxis, requiring immediate medical intervention.
• Persistent cystitis or bladder inflammation lasting more than 48 hours and needing treatment.
• Systemic photosensitivity reactions, such as skin rash, if significant absorption occurs.

When using Hexvix, clinicians should observe specific precautions to minimize risks and ensure accurate diagnostic results.

• Ensure proper bladder emptying before instillation.
• Use sterile technique and avoid contamination of the solution.
• Perform the procedure under blue‑light cystoscopy equipment calibrated according to manufacturer guidelines.
• Monitor patients for signs of allergic reaction during and after administration.
• Advise patients to avoid exposure to strong light sources for 24 hours after the procedure.
• Consider postponing use in patients with active urinary tract infection.
• Document any adverse events in the patient’s record.

Hexvix may interact with other agents or conditions that affect photosensitivity or bladder physiology.

Avoid

• Concurrent use of systemic photosensitizing drugs (e.g., porfimer sodium, aminolevulinic acid).
• Administration immediately after intravesical chemotherapy agents that irritate the bladder lining.

Use with caution

• Patients receiving anticoagulants, as bladder irritation may increase microscopic bleeding.
• Use in individuals with severe renal impairment, requiring careful monitoring of fluid balance.
• Combination with other diagnostic dyes may alter fluorescence interpretation.
• Concurrent use of topical agents that could contaminate the bladder environment.
• Concomitant use of strong analgesics that may mask bladder discomfort.